首页> 外文期刊>Digestion >Well-differentiated neuroendocrine neoplasia: Relapse-free survival and predictors of recurrence after curative intended resections
【24h】

Well-differentiated neuroendocrine neoplasia: Relapse-free survival and predictors of recurrence after curative intended resections

机译:分化良好的神经内分泌肿瘤:无复发生存期和根治性手术后复发的预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Resection with curative intention is the cornerstone of treatment in patients with neuroendocrine tumors. A proportion of patients will relapse after R0 resection, but the factors predictive of recurrence are not well understood. Methods: A database established 1998 at the University Hospital Marburg was queried for all patients with documented R0 resection. Recurrence-free survival and overall survival were estimated using the Kaplan-Meier method. Uni- And multivariate analyses were performed. Results: 180 patients with a median age of 52 years entered the analysis. We observed 77 recurrences after a median time of 2.9 years. 24% of the recurrences occurred later than 5 years after operation. Median recurrence-free survival of the whole cohort was 101 months. In univariate analysis grade by Ki-67, stage, high lymph node ratio and microangioinvasion were significant predictors of recurrence. On multivariate analysis these parameters were confirmed as independent prognostic parameters with stage and microangioinvasion being the most important predictors. Conclusions: After R0 resection of neuroendocrine tumors, postoperative surveillance should be extended to at least 10 years. Patients with distant metastases and microangioinvasion are at high risk of recurrence. Clinical trials of adjuvant treatment protocols are indicated in these patients.
机译:背景:根治性切除是神经内分泌肿瘤患者治疗的基石。一部分患者在R0切除后会复发,但对复发的预测因素尚不清楚。方法:查询1998年在马尔堡大学医院建立的数据库,以记录所有R0切除的患者。使用Kaplan-Meier方法评估无复发生存期和总生存期。进行了单变量和多变量分析。结果:180名中位年龄为52岁的患者进入了分析。在中位时间为2.9年后,我们观察到77例复发。 24%的复发发生在术后5年后。整个队列的中位无复发生存期为101个月。在Ki-67单因素分析评分中,分期,高淋巴结比率和微血管浸润是复发的重要预测指标。在多变量分析中,这些参数被确认为独立的预后参数,其中分期和微血管浸润是最重要的预测指标。结论:R0切除神经内分泌肿瘤后,术后监护应延长至至少10年。远处转移和微血管浸润的患者复发的风险很高。在这些患者中指出了辅助治疗方案的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号